1. New hydrazine and hydrazide quinoxaline 1,4-di-N-oxide derivatives: In silico ADMET, antiplasmodial and antileishmanial activity.
- Author
-
Quiliano M, Pabón A, Ramirez-Calderon G, Barea C, Deharo E, Galiano S, and Aldana I
- Subjects
- Humans, Leishmania infantum drug effects, Leishmaniasis, Visceral drug therapy, Malaria, Falciparum drug therapy, Plasmodium falciparum drug effects, Structure-Activity Relationship, Antiprotozoal Agents chemistry, Antiprotozoal Agents pharmacology, Hydrazines chemistry, Hydrazines pharmacology, Quinoxalines chemistry, Quinoxalines pharmacology
- Abstract
We report the design (in silico ADMET criteria), synthesis, cytotoxicity studies (HepG-2 cells), and biological evaluation of 15 hydrazine/hydrazide quinoxaline 1,4-di-N-oxide derivatives against the 3D7 chloroquine sensitive strain and FCR-3 multidrug resistant strain of Plasmodium falciparum and Leishmania infantum (axenic amastigotes). Fourteen of derivatives are novel quinoxaline 1,4-di-N-oxide derivatives. Compounds 18 (3D7 IC
50 =1.40μM, FCR-3 IC50 =2.56μM) and 19 (3D7 IC50 =0.24μM, FCR-3 IC50 =2.8μM) were identified as the most active against P. falciparum, and they were the least cytotoxic (CC50 -values>241μM) and most selective (SI>86). None of the compounds tested against L. infantum were considered to be active. Additionally, the functional role of the hydrazine and hydrazide structures were studied in the quinoxaline 1,4-di-N-oxide system., (Copyright © 2017 Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF